Clinical Trials: 'Lung Cancer' Category

For a more thorough listing of lung cancer clinical trials, please see ClinicalTrials.gov. Mesothelioma Center elects to list clinical trials that apply specifically to mesothelioma patients; therefore, clinical trials listed in this category likely apply to both lung cancer and mesothelioma.

Lung Cancer news feed.

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

This phase I trial studies the side effects and how well light dosimetry system works during photodynamic therapy with porfimer sodium in treating participants with malignant mesothelioma or non-small cell lung cancer with pleural disease undergoing surgery. Light dosimetry measures the amount of laser light given during photodynamic therapy. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to light. The activated drug may kill tumor cells. Using light dosimetry for intraoperative photodynamic therapy may help doctors estimate how much light is delivered during photodynamic therapy and decide if the treatment should be stopped or continued.

Osimertinib In EGFR Mutant Lung Cancer

This research study is studying a targeted therapy as a possible treatment for Non-Small cell Lung cancer (NSCLC) with an EGFR mutation.

The names of the study drug involved in this study is:

– Osimertinib (Tagrisso)

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

Primary Outcome Measures Progression free survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Secondary Outcome Measures Overall survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Safety analysis (AEs according to CTCAE more

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

An open-label Phase I/II study, with a dose escalation part (Phase I) and a 2-arm randomized part (Phase II), in patients with recurrent SCLC.

Hybrid APC Therapy in Early Central Lung Cancer

This cohort study aims to investigate the clinical value of Hybrid APC for treatment of early central lung cancer.

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

To determine the efficacy of M7824 plus topotecan or temozolomide in relapsed SCLC.

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Purpose: The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

Purpose: A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation Positive non-small cell lung cancer

Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer (STEP PC)

Purpose: This research study is evaluating ways to provide palliative care to patients who have recently been diagnosed with lung cancer

Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers

Purpose CK-301 is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objective of this study is to assess the safety, tolerability and preliminary efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.

Last update: January 19, 2018. 04:57:31 pm.